Select Page

Abstract Number: 897 – Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Presenter: Danai Dima, MDSession: 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early RelapseDate & Time: Monday, December 9, 2024 3:15 PM–3:30 PMLocation: Pacific Ballroom Salons 24-26...

Abstract Number: 891 – Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Presenter: Efstathios Kastritis, MDSession: 652. MGUS, Amyloidosis, and Other Non-Myeloma Plasma Cell Dyscrasias: Clinical and Epidemiological: Ignored no Longer-Progress in AL AmyloidosisDate & Time: Monday, December 9, 2024 3:15 PM–3:30 PMLocation: Pacific...